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Abstract 
 
   Objective. To evaluate the impact of TNFα blockers on the presence of liver fibrosis in 
patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with methotrexate 
(MTX). 
   Methods. Subjects were consecutive patients with RA and PsA who had undergone MTX 
treatment for at least one year +/- TNF blockade for over 6 months. Liver fibrosis was 
assessed using non-invasive transient elastography (FibroScan). Regression models were used 
to compare FibroScan values of RA and PsA patients receiving TNFα blockers with those 
who were not.  
   Results. FibroScan assessments were performed on 51 RA and 43 PsA patients. Compared 
to RA patients, those with PsA were predominantly young males, received lower cumulative 
dosages of MTX and exhibited a higher incidence of liver steatosis and hyperlipidemia. An 
abnormal result was observed in 7.1% of the anti-TNFα-naïve and in 13% of the anti-TNFα-
treated patients in the RA group, and in 30% of the anti-TNFα-naïve and 4.3% of the anti-
TNFα-treated patients in the PsA group (OR = 0.11, 95% CI 0.02 to 0.98). Results of the PsA 
group were robust when adjusted for baseline characteristics. 
   Conclusion.  The results suggest a protective effect of TNFα inhibitors against the 
development of liver fibrosis in patients with PsA. 
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 Longstanding treatment with methotrexate (MTX) in patients with rheumatoid arthritis 
(RA) or psoriatic arthritis (PsA) is associated with increased liver toxicity. Institutional 
guidelines for monitoring of MTX-associated hepatotoxicity are effective in most countries 
and include periodic determination of aminotransferase serum levels or liver biopsy (1). 
However, the role of liver biopsy has been questioned (2,3), and it was proposed that 
detection of abnormal serum levels of the aminoterminal peptide of type III procollagen might 
identify patients at risk, thereby reducing the number of biopsies in psoriatic patients by 45% 
(4). Recently, transient elastography (FibroScan) was accepted as an alternative method to 
quantify liver tissue stiffness (5). This method has been widely used and validated in patients 
with viral hepatitis where the results correlate histologically with hepatic fibrosis (6). 
Anti-TNFα treatment for concomitant rheumatic disorders in patients with chronic 
hepatitis C (7) and non-alcoholic steatohepatitis (NASH) (8) showed a favorable outcome of 
the liver disease. We hypothesized that MTX-related liver toxicity could also benefit from 
anti-TNFα treatment, and therefore performed a prospective observational study to assess 
liver fibrosis using FibroScan in a population consisting of patients with PsA and RA on long-
term treatment with MTX who had been started on additional TNFα-blockade. 
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Patients and Methods 
 We included RA and PsA patients with a valid baseline FibroScan (see Supplementary 
File 1 for detailed information) who had been consecutively recruited from the outpatient 
clinic of the Department of Rheumatology and Immunology at Bern University Hospital, 
Switzerland (see Supplementary File 2 for the patient flow). 
 All patients had been receiving MTX treatment for at least one year with or without 
anti-TNF blockade for over 6 months. RA and PsA diagnoses were based on established 
classification criteria (9,10). Demographic information was obtained through direct 
questioning (age, sex, BMI, diabetes mellitus, alcohol consumption, MTX application, folic 
acid supplementation) or using retrospective chart reviews (disease duration, MTX 
cumulative dose, hyperlipidemia, steatosis, hepatitis). Measurements of liver enzyme levels 
during MTX exposure were screened for any elevations (over twice the upper limit of ASAT 
or ALAT levels).  
Analysis. Patient characteristics stratified by disease (RA and PsA) and TNFα 
treatment were compared using the Kruskal-Wallis rank test for continuous variables and 
Fisher’s exact test for categorical variables. To describe the association of anti-TNFα 
treatments with abnormal FibroScan measurements in terms of odds ratios, we fitted logistic 
regression models with FibroScan assessments as the outcome variables. To assess whether 
the association with anti-TNFα treatment differed between RA and PsA patients we included 
in the regression models an appropriately constructed effect modification term and reported 
its p-value, allowing us to determine the statistical likelihood that effect modification was 
present. In sensitivity analyses we included additional baseline characteristics in the logistic 
regression models to adjust for BMI, age, gender, alcohol intake, diabetes mellitus, disease 
duration, cumulative MTX dose and cumulative folic acid dose, and tested for the interaction 
between each of these factors with MTX and anti-TNFα treatments. All p-values are 2-sided 
and analyses were performed in Stata version 10 (Stata Corporation, College Station, Texas).  
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Results 
Patients’ baseline characteristics 
 Table 1 demonstrates the differences in demographics, disease- and treatment-related 
factors, comorbidities and FibroScan findings between 51 RA and 43 PsA patients (all with 
oligo- or polyarticular disease courses) either treated with MTX alone or with a combination 
of MTX and a TNFα blocker. Compared to RA patients, those with PsA were younger and 
consisted of more males. PsA patients had received a lower cumulative dose of MTX with a 
trend to shorter disease duration compared to their RA counterparts. There was no difference 
between patients groups with regard to weekly MTX dose, route of MTX administration, dose 
of folic acid supplementation, or co-medication with non-steroidal anti-inflammatory drugs or 
prednisone. At the time of the FibroScan exam all patients were at least in partial remission.  
When comparing the incidence of comorbidities between PsA and RA patients we 
found no differences in body mass index (BMI), current or past alcohol consumption, or 
concomitant diabetes mellitus. More patients in the PsA group had hyperlipidemia and 
sonographically detected liver steatosis (7 PsA vs. no RA patients and 7 PsA vs. 1 RA patient, 
respectively).  
FibroScan measurements and association with anti-TNFα treatment   
 When analysing only patients with a valid FibroScan exam, we found abnormal results 
in 9.8% of RA patients and 16.3% of PsA patients. An abnormal result was observed in 2 of 
28 anti-TNFα-naïve (7.1%) and in 3 of 23 anti-TNFα-treated (13%) patients in the RA group, 
but in 6 of 20 anti-TNFα-naïve (30%) and in only 1 of 23 anti-TNFα-treated (4.3%) PsA 
patients. When stratified by anti-TNFα treatment, these findings resulted in a crude OR of 
1.95 with a 95% CI of 0.30 to 12.8 for the RA group and a crude OR of 0.11 with a 95% CI of 
0.02 to 0.98 for the PsA group (p = 0.05 for interaction; Table 2). These findings were 
confirmed by the higher absolute mean FibroScan value in the anti-TNFα-naïve PsA group 
(8.1 kPa) compared to the other groups (FibroScan values between 4.9 and 5.5 kPA, p-value 
for trend 0.06; Figure 1). Our results were robust to adjustment for BMI, age, gender, alcohol 
intake, diabetes mellitus, disease duration, cumulative MTX dose and folic acid dose, with 
adjusted ORs ranging from 0.02 to 0.13 in the PsA group. When adjusting for all variables, 
we obtained an OR of 0.03 (95% CI 0.02 to 1.11). Adjustments in the RA group resulted in a 
slightly more heterogenous picture. Whereas adjustment for BMI, age, gender, alcohol intake 
and diabetes mellitus did not change the OR, adjustment for disease duration, cumulative 
MTX dose and folic acid dose yielded an adjusted OR of 1.14. However, adjusting for all 
variables still showed an OR of 1.73 (95% CI 0.16 to 18.2) (Table 2).  
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Discussion 
     This observational study is the first to show that treatment with TNFα blockers may 
exert a protective effect against liver fibrosis in patients with PsA treated with MTX. This 
finding was robust to the adjustment for potentially confounding factors. RA patients had 
lower FibroScan values than PsA patients in the MTX alone group, despite a higher 
cumulative dosage of MTX. These low FibroScan values may have masked a potential 
antifibrotic effect of TNF inhibition in the RA patient cohort. The discrepancy between the 
PsA and RA MTX alone groups supports earlier notions that disease-associated factors, either 
pathogenesis- or comorbidity-linked, play an important role in liver fibrosis.  
 While this is the first study that has used a mixed cohort of RA and PsA patients to 
report benefits of anti-TNFα treatment for liver fibrosis, it has its limitations. The number of 
patients was low and the duration of anti-TNFα treatment compared to MTX treatment was 
short. In addition, some of the data collection (e.g. disease duration, cumulative MTX dose, 
comorbidities) had to be done retrospectively, as we included patients with longstanding 
disease. However, we tried to minimize the impact of this potential bias by blinding the chart 
reviewer to the FibroScan outcome.  
Our results are in good agreement with the favorable hepatological outcomes 
previously described in patients with chronic hepatitis C (7) or NASH (8) following anti-
TNFα treatment for concomitant rheumatic disorders. These human data, as well as recent 
results obtained from an experimental model of NASH in the rat (12), underline the 
pathogenic role of TNFα in acute and chronic liver disorders. There is an abundance of 
indirect evidence that TNFα might be involved in the pathogenesis of liver fibrosis in 
systemic rheumatic diseases caused either by the inflammatory rheumatic processes 
themselves or by concomitant comorbidities. For instance, TNFα plays a key role inducing 
fibrogenic growth factors such as transforming growth factor beta (TGFβ) (13) and 
connective tissue growth factor (CTGF) (14) in fibrotic liver diseases. Additionally, liver 
fibrosis is thought to be the result of chronic portal inflammation in non-alcoholic fatty liver 
disease (15) that is often linked to obesity (16) and dyslipidemia (17), comorbidities that 
along with diabetes mellitus define the metabolic syndrome that is often associated with 
psoriasis (18). Moreover, patients with MTX-treated psoriasis and risk factors for liver 
disease, particularly type 2 diabetes or obesity, are at higher risk of developing severe liver 
fibrosis compared to those without such risk factors, even when lower cumulative MTX doses 
are given (19). Accordingly, in our study we found a higher prevalence of liver steatosis and 
dyslipidemia at baseline in the PsA group compared to the RA group.  
 We cannot discern whether the higher frequency of liver pathology in PsA patients is 
due to associated hepatotoxic comorbidities such as liver steatosis rather than to liver disease 
caused by the chronic immunologically mediated inflammatory process itself. Irrespective of 
the cause of liver inflammation, however, the results of this study provide the first evidence 
that anti-TNFα treatment is likely to protect against the evolution of liver fibrosis in PsA 
patients. To validate the findings of our study, prospective studies with repeated FibroScans in 
PsA patients before and after starting MTX and/or anti-TNFα treatment will be needed.  
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Figure Legends 
 
Figure 1.  FibroScan measurements expressed in kPa. Data on patients belonging to each 
disease and treatment group are expressed as means of values with a 95% confidence interval. 
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Table 1. Patients’ baseline characteristics 
 
 Rheumatoid Arthritis Psoriatic Arthritis 
 TNF – (n=28) 
TNF + 
(n=23) 
TNF – 
(n=20) 
TNF + 
(n=23) 
p-
value 
Age [years, SD] 60.3 (9.2) 57.0 (12.5) 51.9 (14.1) 51.3 (10.9) 0.02 
Females [numbers, %] 16  (57.1) 17  (73.9) 6 (30.0) 7 (30.4) 0.006 
BMI [kg/m2, SD] 26.0 (3.8) 25.4 (4.4) 26.4 (3.8) 27.0 (4.5) 0.60 
Disease duration (years, SD) 17.3 (10.8) 13.0 (11.2) 9.5 (7.6) 11.8 (11.2) 0.07 
MTX dose per week (mg, 
SD) 16.4 (3.8) 16.0 (3.3) 16.1 (4.6) 15.4 (5.4) 
0.87 
MTX cumulative dose (g, 
SD) 6.9 (5.4) 3.8 (3.2) 2.7 (2.3) 3.7 (3.2) 
0.001 
Folic acid cumulative dose 
(g, SD) 11.8 (3.5) 9.7 (4.4)  9.8 (5.0)  9.4 (3.0) 
0.11 
Diabetes mellitus [numbers, 
%] 2 (7.1) 1 (4.3) 3 (15.0) 3 (13.0) 
0.64 
Steatohepatitis [numbers, %] 0 (0.0) 1 (4.3) 4 (20.0) 3 (13.0) 0.05 
Hyperlipidemia [numbers, 
%] 0 (0.0) 0 (0.0) 4 (20.0) 3 (13.0) 
0.009 
Any alcohol consumption 
[numbers, %] 4 (14.3) 3 (13.0) 7 (35.0) 5 (21.7) 
0.28 
Daily alcohol consumption 
(g, SD) 4.3 (12.8) 4.6 (12.3) 11.3 (16.6) 4.3 (10.4) 
0.24 
Elevated liver enzymes 
[numbers, %] 3 (10.7) 9 (39.1) 
7 (35.0) 10 (43.5) 0.10 
 
 
Baseline characteristics of the 94 patients with rheumatoid arthritis and psoriatic arthritis, 
treated with (TNF+) or without (TNF-) TNFα blockers, are presented as means with standard 
deviations or numbers with percentages. P-values are derived using the Kruskal-Wallis rank 
test for continuous variables and the Fisher’s exact test for categorical variables.   
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Table 2. Association of pathologic FibroScan measurements with anti-TNFα treatment 
in RA and PsA patients 
   
 
 
variable adjustment 
RA 
(n=51) 
OR*, 95% CI  
PsA 
(n=43) 
OR*, 95% CI 
 
p-value for 
interaction**  
crude  1.95 (0.30 to 
12.8) 
0.11 (0.02 to 
0.98)      
      0.05 
adjusted for BMI, age, gender 1.93 (0.27 to 
13.7) 
0.03 (0.002 to 
0.64) 
      0.03  
adjusted for alcohol intake 1.94 (0.29 to 
13.0) 
0.13 (0.08 to 
1.25) 
0.055 
adjusted for diabetes mellitus 1.89 (0.29 to    
12.5) 
0.10 (0.01 to 
0.97) 
0.048 
adjusted for disease duration, cumulative MTX dose 
and folic acid dose 
1.14 (0.14 to 
9.13) 
0.02 (<0.01 to 
0.61) 
0.077 
adjusted for all variables 1.73 (0.16 to 
18.2) 
0.03 (0.001 to 
1.11) 
0.063 
 
 
* OR=odds ratios 
** p  - values and 95% confidence intervals (CI) are derived from logistic regression models. 
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Supplementary File 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Flow chart 
Sixty-five RA and 87 PsA patients from the outpatient clinic of the Department of 
Rheumatology and Clinical Immunology & Allergology at the University Hospital of Bern, 
Switzerland, were asked to participate in this observational study. Six RA patients and 37 PsA 
patients refused to participate. A total of 109 patients (59 with RA and 50 with PsA) were 
referred to the Institute of Clinical Pharmacology at Bern University Hospital, Switzerland, in 
order to undergo a transient elastography (FibroScan) exam. Of this population, 8 RA and 7 
PsA patients had invalid FibroScan measurements for technical reasons. Valid baseline 
FibroScan results were obtained from 51 RA and 43 PsA patients.  
Underwent baseline liver scan:
109 patients
- 59 Rheumatoid Arthritis
- 50 Psoriatic Arthritis
Valid baseline liver scan: 
94 patients
- 51 Rheumatoid Arthritis
- 43 Psoriatic Arthritis
Eligible for participation:
154 patients
- 65 Rheumatoid Arthritis
- 87 Psoriatic Arthritis
Refused to participate:
43 patients
- 6 Rheumatoid Arthritis
- 37 Psoriatic Arthritis
Non-valid liver scan:
15 patients
- 8 Rheumatoid Arthritis
- 7 Psoriatic Arthritis
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